Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer DetectionPRNewsWire • 10/22/23
Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual CongressPRNewsWire • 10/20/23
Exact Sciences to Present Late-Breaking Data from Pivotal BLUE-C Study on Next-Generation Cologuard at ACG 2023PRNewsWire • 10/09/23
Which Is the Better Cancer-Testing Healthcare Stock: Exact Sciences or Guardant Health?The Motley Fool • 10/08/23
Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution BioscienceBusiness Wire • 09/12/23
Watchmaker Genomics Announces Co-Exclusive License to Disruptive DNA Methylation Technology and Strategic Supply Agreements with Exact SciencesBusiness Wire • 08/30/23
Exact Sciences Lab and OncoExTra Test Selected by National Cancer Institute for ComboMATCH Clinical TrialsPRNewsWire • 08/30/23
Cathie Wood Has 5 ‘Strong Buy' ARK Innovation Holdings That Aggressive Growth Investors Can Grab Now and Hold Forever24/7 Wall Street • 08/24/23